Key points from article :
London-based biotech startup 199 Biotechnologies is pioneering epigenetic reprogramming to tackle ageing and chronic diseases at their root. Epigenetic changes—chemical modifications that regulate gene activity—accumulate with age and contribute to cellular decline and disease susceptibility. By combining bioengineering, AI, microfluidics, and genetics, 199 Bio aims to reverse these age-related changes and restore cellular health using reprogramming technologies based on the famous Yamanaka factors, often called a “biological cheat code” for their ability to reset cell identity.
Since its launch last year, the company has rapidly grown and is already testing in large mammal models. Their key targets include cancer, neurodegenerative diseases, microvascular rejuvenation, ovarian ageing, and even a rare muscular dystrophy. CEO Dr. Djordjevic emphasizes a moral urgency to accelerate clinical translation, acknowledging risks like teratomas but arguing that patients with limited treatment options need faster access to promising therapies.
199 Bio plans to start human trials within two years, with an initial focus on China due to its supportive regulatory environment and large patient pool. They are exploring multiple therapeutic platforms—such as mRNA, cell therapy, ex vivo reprogramming, and organ-on-a-chip technologies—to optimize delivery of epigenetic factors. Guided by expert advisors including Professor João Pedro de Magalhães, the company is committed to swiftly moving from the lab to the clinic to benefit patients with serious conditions.
